Federal contract award
75A50118C00013
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $62.6M |
| Current contract value | $62.6M |
| Potential contract value / ceiling | $70.6M |
| Start date | Sep 24, 2018 |
| Current end date | May 31, 2025 |
| Potential end date | May 31, 2025 |
| Latest award activity | May 13, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 13, 2026 | P00012 | $-1 | THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELING YEAR FUNDS FROM REQUISITION OS252049 IN THE AMOUNT OF (-$1.16) FROM CLIN00002. |
| Mar 17, 2025 | P00011 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0006 OPTION 2C THROUGH MAY 31, 2025, AT NO ADDITIONAL COST TO THE GOVERNMENT DUE TO THE 2-MONTH DELAY IN SUBMISSION OF THE 510(K) PACKAGE TO THE FDA AND UPDATE ARTICLE I. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.